ReviewAdvances in experimental medicine and biology2020
Meningioma Tumor Microenvironment.
Review in Advances in experimental medicine and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Two-sample Mendelian randomization analysis of 91 circulating inflammatory protein levels and meningioma.Medicine · 2025Article
- Tumour-associated macrophages in human meningiomas.PloS one · 2025Article
- CAR-T-cell therapy in meningioma: current investigations, advancements and insight into future directions.Annals of medicine and surgery (2012) · 2024Review
- Novel Human Meningioma Organoids Recapitulate the Aggressiveness of the Initiating Cell Subpopulations Identified by ScRNA-Seq.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Lateral ventricle meningiomas in children: clinicopathological and neuroradiological features.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Article
- Inflammatory factors and risk of meningiomas: a bidirectional mendelian-randomization study.Frontiers in neuroscience · 2023Article
- CDK 4/6 inhibitors for the treatment of meningioma.Frontiers in oncology · 2022Review
- M2-Macrophage-Derived Exosomes Promote Meningioma Progression through TGF-Journal of immunology research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment consists of noncancerous cells, such as immune cells and fibroblasts, and the proteins produced by these cells as well as the extracellular matrix components in the environment around a tumor. Tumor influences the behavior of the cells present in the surrounding environment, while the cells in the tumor microenvironment modulate the evolution of the tumor. Little is known about the microenvironment of meningioma, the most common benign intracranial tumor. Here, we review the current knowledge of the tumor microenvironment of meningioma and discusses its importance in meningioma tumorigenesis as well as in the designation of novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.